Merck Says Sac-TMT Trial Met Overall Survival Endpoint
Merck said its TroFuse-015 trial found sacituzumab tirumotecan improved overall survival versus physician’s choice in third-line or later gastroesophageal adenocarcinoma.
Merck said its TroFuse-015 trial found sacituzumab tirumotecan improved overall survival versus physician’s choice in third-line or later gastroesophageal adenocarcinoma.